Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data49
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs31
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data30
Economic evaluation in psychiatric pharmacogenomics: a systematic review29
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy23
Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium23
Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy19
Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis17
Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study17
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle16
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection15
Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan15
Does the RAAS play a role in loss of taste and smell during COVID-19 infections?15
Nine-gene pharmacogenomics profile service: The Mayo Clinic experience14
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States14
Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications13
Pharmacogenetic information in Swiss drug labels – a systematic analysis13
miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders12
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population12
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel11
Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis10
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review10
The variants at FLNA and FLNB contribute to the susceptibility of hypertension and stroke with differentially expressed mRNA10
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model10
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-199
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore9
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review9
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis9
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment8
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review8
Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population8
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals8
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges7
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer7
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis7
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors7
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice7
Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists7
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?6
Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes6
Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers6
Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China6
Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer6
HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure6
A review of the existing literature on buprenorphine pharmacogenomics6
The need of a multicomponent guiding approach to personalize clopidogrel treatment6
0.019023895263672